论文部分内容阅读
目的评价天津市艾滋病(AIDS)初治患者,应用高效抗逆转录病毒治疗(HAART)的疗效、安全性和预后。方法将在天津市传染病医院就诊的62例AIDS患者,随机分成治疗组(45例)及对照组(17例);治疗组应用一线HAART方案:AZT/D4T+3TC+NVP/EFV。观察两组患者的临床表现、免疫功能变化及预后。结果(1)HAART治疗组与对照组患者基线CD4T细胞计数差异无统计学意义(P>0.5);治疗组的45例患者,HAART前CD4T细胞计数均值为73/μl;HAART后3、6、12个月时分别为120/μl(39例)、139.5/μl(30例)和200/μl(22例)。(2)治疗组患者应用HAART后,机会性感染、肿瘤的发生率和病死率分别为40%和4.44%,均显著低于对照组的88.24%和47.06%(P<0.01)。(3)初治患者一线HAART治疗的有效率为95.55%(43/45),有17.78%(8/45)的患者因药物不良反应而调整HAART方案。结论天津市AIDS患者对一线HAART有较好的疗效,随着HAART疗程的延长,免疫功能得到恢复并改善了预后,存在药物不良反应和资源有限等问题。
Objective To evaluate the efficacy, safety and prognosis of patients with newly diagnosed AIDS in Tianjin using high effective antiretroviral therapy (HAART). Methods Totally 62 AIDS patients treated in Tianjin Infectious Diseases Hospital were randomly divided into treatment group (45 cases) and control group (17 cases). The treatment group received first-line HAART regimen: AZT / D4T + 3TC + NVP / EFV. The clinical manifestations, immune function changes and prognosis of the two groups were observed. Results (1) There was no significant difference in baseline CD4 T cell count between HAART group and control group (P> 0.5). In the 45 patients in the treatment group, the average pre-HAART CD4 T cell count was 73 / At 12 months they were 120 / μl (39 cases), 139.5 / μl (30 cases) and 200 / μl (22 cases), respectively. (2) In the treatment group, the incidence of opportunistic infections, tumor and mortality were 40% and 4.44%, respectively, which were significantly lower than 88.24% and 47.06% (P <0.01) of the control group. (3) The effective rate of first-line HAART in first-line patients was 95.55% (43/45), and 17.78% (8/45) in patients with HAART adjusted for HAART due to adverse drug reactions. Conclusion AIDS patients in Tianjin have better curative effect on first-line HAART. With the prolongation of HAART treatment, immune function is restored and prognosis is improved. There are some problems such as adverse drug reactions and limited resources.